Audit: QRS - Sesame Seed Extract for Health & Longevity

Audit conducted on 13/08/2026 10:50 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to Therapeutic Protocol (ER 363–381) and Practical Considerations (ER 418–422), time cells to ER 418/392/165, gates to Key Interactions & Contraindications (ER 315–341), benefit/risk tiers to the ER H4 headings, monitoring rows to the ER biomarker table (ER 448–458).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The at-a-glance carries the ER’s own hedges (“findings disagree”, “a few small trials”, “modest, genuinely uncertain payoff”); marker_8 keeps “No established target; track the change from the individual’s own baseline” verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	All seven ER avoid-populations remain in the STOP gate at full strength, including “Pregnancy and breastfeeding”; no caution-level item was promoted or demoted.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid” list, Key Interactions only from the ER’s interaction bullets; no Benefit- or Risk-Modifying Factor content appears in the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, no author names, no NCT identifiers, no manufacturer names anywhere in the file; the only proper nouns are generic drug names, each present in the same ER bullet.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear outside the fixed template subline.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register matching the ER; the at-a-glance mirrors the Conclusion’s own framing including “low-cost, low-risk addition with a modest … payoff”.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Concrete doses, thresholds and biomarker targets throughout, with an even-handed benefit/risk presentation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive constructions (“Range used in the isolated-lignan trials”, “Once-daily dosing; splitting is unnecessary”) rather than instructions issued to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical directives; the gates report ER-stated populations and interactions rather than instructing the reader.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or equivalent in the QRS voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	Grep for “you”, “your”, “we”, “our”, “reader” returns no match in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	The at-a-glance is fully plain-language; technical terms elsewhere (CYP3A4, hs-CRP, HbA1c, IgE) are load-bearing biomarker and interaction names carried from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items are short noun phrases, benefit/risk tiers are semicolon-joined headings, and the cadence paragraph compresses the ER’s monitoring prose (ER 446) to four sentences.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by the same grep as 2.6; no second-person address anywhere.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges (LDL < 80 mg/dL, hs-CRP < 0.5 mg/L, HbA1c 4.8–5.4%) rather than conventional clinical cutoffs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Daily home blood-pressure logging, a nine-marker panel, and evening fat-paired dosing are presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward general-population framing; the monitoring targets are explicitly tighter than conventional lab flags.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance positions the intervention as a modest, uncertain add-on rather than a headline benefit, matching the ER’s audience-calibrated Conclusion.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging”; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	No colloquialisms (“pill”, “shot”, “meds”, “bad reaction”) anywhere; the plain-language wording confined to the at-a-glance is mandated by item 7.4 and echoes the ER Conclusion’s own phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	A structural diff against core/qrs/QRS.html with variable regions masked shows zero differences in any heading, gate label, tier label or table header.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names are present; the repeatable marker_#_* and qualitative_item_# patterns are expanded to nine and five instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The masked diff shows the website="evidence_review", website="audit" and website="full_review" spans, the stylesheet, the footer disclaimer and all structural comments are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty; every benefit tier, risk tier, gate list, protocol and monitoring source carries content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose”, “Best time of day” and “Whole-food alternative” are the ER’s bold protocol labels verbatim (ER 363, 365, 371); gate items reuse the ER’s bold interaction labels with the post-em-dash qualifier stripped per 9.4.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	All nine marker names match the ER biomarker table exactly, including “Systolic / Diastolic Blood Pressure” and “Serum Gamma-Tocopherol”.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Unicode emoji grep returns no match; the ER’s tier squares and “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section was condensed rather than extended: 12 ER protocol bullets reduced to 3 cells, 9-bullet interaction prose reduced to 9 short noun phrases with trimmed example-drug lists, benefit/risk paragraphs reduced to headings, and the ER’s monitoring paragraph compressed to a four-sentence cadence line.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” precedes it as permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of the values are repeated in <head> or <body> content.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon requiring it; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: sesame_seed_extract_2026-0813-0837_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0813-1038, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word carrying no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s own name on disk exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; git_user and git_issue are bare, duration is correctly quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Sesame Seed Extract for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Sesame Seed Extract for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/13/2026”, the correct reformatting of 2026-0813-1038.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header contains only the title and the template’s fixed subline; the ER’s “Also known as” line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All five clauses map onto the ER Conclusion (ER 488–492): the blood-pressure drop, the disagreeing lipid analyses, the glucose signal, the vitamin E effect, and the allergy/enzyme safety picture.
7.2	[at_a_glance] is no longer than 60 words	🟢	Scripted word count returns 59.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause resolves to a separate Conclusion sentence; the closing phrase reproduces “a low-cost, low-risk addition with a modest and genuinely uncertain payoff” (ER 492).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “the upper blood-pressure number”, “blood-fat findings”, “blood-sugar markers”, “the body’s breakdown of vitamin E” and “a liver enzyme that clears many medicines” in place of systolic, lipid, glycemic, tocopherol catabolism and CYP3A4.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No author name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	“a few points” replaces the ER’s −3.66 mmHg; no confidence intervals or pooled estimates appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the “Populations who should avoid Sesame Seed Extract” list at ER 333–341.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete one-to-one coverage of the ER’s seven avoid-populations, in the ER’s own order.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven discrete <li> elements at lines 542–548 inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Rationale clauses stripped throughout: “regardless of extract purity claims”, “given the untested estrogen-like metabolite”, “for whom no safety data at supplemental lignan doses exist” and “where CYP3A4 inhibition can push levels into the toxic range” are all absent.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The threshold “(seated systolic below 100 mmHg)”, the staging “(active or in surveillance)”, and the qualifiers “without a completed supervised oral food challenge” and “without international normalized ratio monitoring access” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets contain no ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations and the section is correspondingly populated, so the emptiness constraint is not breached.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to the nine interaction bullets at ER 315–331.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Complete coverage of the nine ER interaction bullets; the warfarin entry is retained because the ER’s contraindication is the narrower conditional case (no INR monitoring access), not the interaction itself.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine discrete <li> elements at lines 556–564 inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “— caution”, “— monitor”, “— additive, intended” and “— additive and synergistic” suffixes and all mechanistic sentences are stripped; “Warfarin”, “Vitamin E supplements” and “Fish oil” are reduced to the bare key fact.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every drug class retains at least one named example (lisinopril, losartan, amlodipine, hydrochlorothiazide, atenolol, simvastatin, felodipine, tacrolimus, cyclosporine, apixaban, metformin, glipizide, ibuprofen, naproxen); lists were shortened, never dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets contain no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine such interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells draw on the ER Therapeutic Protocol bullets (ER 363, 365, 371, 375, 381), with the absorption detail from the ER’s fat-containing-meal mitigation (ER 358).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and the whole-food alternative are the three decision-relevant bullets; the remaining ER bullets are background (half-life, genotype, sex, baseline biomarkers) rather than actionable steps.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains twelve bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; e.g. action_1_sub combines the 60 mg blood-pressure floor (ER 363) with the over-70 titration rule (ER 381).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure (ER 418), vitamin E retention (ER 165) and blood lipids (ER 418) are the three endpoints for which the ER states an onset window.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Blood pressure and vitamin E retention are the ER’s two High-tier benefits and occupy cells 1 and 2; blood lipids is a Medium-tier benefit and occupies cell 3.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; time_1_sub pairs the ER’s “Nothing measurable happens in the first fortnight” (ER 418) with the 45-day washout (ER 392).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect data, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve entries correspond to the twelve H4 headings under ER Expected Benefits (ER 153–227).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 521–532, each carrying the fixed tier label.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER’s H4 heading alone; no Magnitude figures, mechanisms or trial references carried through.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span; the ER’s “⚠️ Conflicted” markers were also correctly dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven entries correspond to the seven H4 headings under ER Potential Risks & Side Effects (ER 251–295).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 576–587, each carrying the fixed tier label.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER’s H4 heading alone; the prevalence figures, IC50 value and 20-HETE percentages are all absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the ER’s glossary expansions (IgE, anaphylaxis) were correctly dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence both come from ER Monitoring Protocol & Defining Success (ER 446–458).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows are present in ER order, with targets and rationale reproduced exactly, including the non-numeric gamma-tocopherol entry.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 706 compresses the ER’s cadence prose: baseline panel, conditional IgE, daily-then-weekly blood pressure, 8-week and 6–12-month bloodwork, and 1/4-week checks on warfarin or narrow-margin CYP3A4 substrates.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the qualitative-marker list at ER 462–466.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Five of five reproduced verbatim and in ER order: lightheadedness on standing, morning energy and daytime fatigue, sleep continuity, joint stiffness on waking, and oral itching or throat tightness after dosing.

Issues 13/08/2026 10:50

Pass rate 100.00%. No issues found.

Issues 13/08/2026 10:43

1. 9.5 — Example drug names dropped: The named example drugs from the ER’s interaction parentheses are dropped entirely from four [caution_items] (QRS lines 556, 557, 559, 560), leaving only drug classes — e.g. the ER’s “ACE inhibitors (lisinopril, ramipril) … ARBs (losartan) … calcium channel blockers (nifedipine, amlodipine)” (ER line 315) becomes bare class names, and the CYP3A4 bullet loses (simvastatin, atorvastatin), (felodipine), (tacrolimus, cyclosporine) and (apixaban, rivaroxaban) (ER line 317).

Fixes 13/08/2026 10:43

1. 9.5 — Example drug names restored: Reinstated the ER’s named example drugs in four [caution_items] in trimmed form — “Antihypertensive medications: ACE inhibitors (lisinopril), ARBs (losartan), calcium channel blockers (amlodipine), diuretics (hydrochlorothiazide), beta-blockers (atenolol)”; “CYP3A4 substrates with narrow margins: statins (simvastatin), calcium channel blockers (felodipine), immunosuppressants (tacrolimus, cyclosporine), direct oral anticoagulants (apixaban)”; “Glucose-lowering medications: metformin, sulfonylureas (glipizide), insulin”; and “Over-the-counter medications: NSAIDs (ibuprofen, naproxen), aluminum- or magnesium-containing antacids”.